ArcherDX

General Information
Business:

 

We are a leading genomics company democratizing precision oncology. We offer a suite of products and services that are highly accurate, personal, actionable and easy to use in local settings. This empowers clinicians to control the sample, data, patient care and economics. Additionally, our products and services enable biopharmaceutical companies to cost-effectively accelerate drug development. We believe these benefits will drive broader adoption of precision oncology throughout the therapeutic continuum, improving patient care. Our product development platform, with our proprietary Anchored Multiplex PCR, or AMP, chemistry at the core, has enabled us to develop industry-leading products and services that optimize therapy and monitor cancer.

Industry: IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Employees: 337
Founded: 2013
Contact Information
Address 2477 55th Street, Suite 202, Boulder, CO 80301, US
Phone Number (877) 771-1093
Web Address http://www.archerdx.com
View Prospectus: ArcherDX
Financial Information
Market Cap
Revenues $55.9 mil (last 12 months)
Net Income $-54.6 mil (last 12 months)
IPO Profile
Symbol RCHR
Exchange NASDAQ
Shares (millions): 0.0
Price range $0.00 - $0.00
Est. $ Volume $100.0 mil
Manager / Joint Managers J.P. Morgan/ BofA Securities
CO-Managers Stifel/ Evercore ISI
Expected To Trade:
Status: TBA
Quiet Period Expiration Date:
Lock-Up Period Expiration Date:
SCOOP Rating
Rating Change